$0.21
+0.00 (+1.50%)
JOB News7 articles
AbbVie's $65B Surge Outpaces Apogee Acquisition Cost by Sixfold
AbbVie's stock surge added $65B in market cap, six times its $10.9B Apogee deal cost, as Skyrizi approval and immunology demand offset Humira declines.
AbbVie Acquires Apogee Therapeutics for $10.9B in Cash, Bolstering Pipeline
AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics, adding a promising eczema treatment to its pipeline as it seeks to offset declining Humira sales.
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
Apogee Therapeutics stock jumped 47% after AbbVie agreed to buy the company for $135.11 per share in cash, adding late-stage eczema drug zumilokibart.
AbbVie to Buy Apogee in $10.9B Deal to Boost Immunology Pipeline
AbbVie acquires Apogee Therapeutics for $10.9 billion, paying a 49.49% premium for experimental eczema drug zumilokibart, as it seeks to bolster its immunology franchise.
AbbVie Nears $10.9B Apogee Takeover, Healthcare Stocks in Focus
AbbVie is reportedly close to acquiring Apogee Therapeutics for $10.9 billion in cash, offering a roughly 60% premium. A deal could be announced Monday, putting healthcare stocks in the spotlight.
ON Semiconductor Shares Surge on Major EV Chip Deals with Geely and NIO
ON Semiconductor shares jumped 8% after announcing expanded silicon carbide chip deals with Geely and NIO for 900V electric vehicle platforms.
Geely Eyes 6.5M Annual Sales by 2030, Intensifying Rivalry with BYD
Geely sold a record 709,358 vehicles in Q1 2026, with exports up 126%. The company aims for 6.5 million annual sales by 2030, challenging BYD domestically and abroad.